INTREPID Alliance Launches Open-Access Antiviral Toolbox to Address Global R&D Gaps
核心洞察
The INTREPID Alliance (搜索) has launched an open-access Antiviral Toolbox featuring a Registry of Antiviral Compound Libraries to support global research efforts in pandemic preparedness.
Current antiviral development reveals critical gaps, with only 27 compounds in clinical development for 12 viral families beyond Coronaviridae (搜索), and no clinical efforts for four pandemic-potential viral families.
The platform provides essential resources including compound libraries, development landscape reports, drug development tools, and pro bono advisory services to accelerate small-molecule antiviral discovery.
The INTREPID Alliance (搜索) announced the launch of its Antiviral Toolbox, an open-access platform designed to address critical gaps in global antiviral research and development that threaten pandemic preparedness. The curated resource provides researchers worldwide with essential tools and compound libraries to accelerate the identification and development of small-molecule antivirals (搜索) for priority viruses of pandemic and endemic concern.
Critical Gaps in Antiviral Development Pipeline
INTREPID's latest review of the global antiviral R&D landscape reveals alarming deficiencies in pandemic preparedness. Beyond Coronaviridae (搜索), only 27 antiviral compounds are currently in clinical development to tackle 12 viral families and their multiple diseases of greatest pandemic concern. More concerning, four viral families with pandemic potential—Paramyxoviridae (搜索), Hantaviridae (搜索), Peribunyaviridae (搜索), and Togaviridae (搜索)—have no clinical development efforts underway.
"Without increased focus and investment in antiviral drug development, the world is at risk of facing a devastating impact from future outbreaks of new and known viruses," said James Anderson, Executive Director of R&D Innovation at the International Federation of Pharmaceutical Manufacturers & Associations (搜索) (IFPMA) and Chair of the INTREPID Alliance (搜索) Board.
Comprehensive Resource Platform
The Antiviral Toolbox comprises four key components designed to support researchers at all stages of drug development:
Registry of Antiviral Compound Libraries provides a curated list of accessible compound libraries for antiviral screening, sourced from publicly disclosed academic institutions, corporate, and commercial vendor listings.
Antiviral Development Landscape offers INTREPID's bi-annual landscape report and interactive pipeline, along with deep-dive topic reports that provide comprehensive analysis of small-molecule antiviral compounds in preclinical and clinical development globally.
Drug Development Tools include essential resources such as published INTREPID Alliance (搜索) Target Compound Profiles, Target Product Profiles, and cell and animal models for specific viral families, available to help drug discoverers and developers at all stages of research.
Pro Bono Advisory Services create opportunities for drug discoverers and developers to connect with INTREPID's team of experts to discuss potential strategies and approaches to address challenges along their drug development journey.
Supporting Small Biotechnology Companies
The timing of this resource launch addresses a critical need in the biotechnology sector. "The INTREPID Alliance (搜索) Antiviral Toolbox comes at a critical time, especially for small biotechnology companies that have limited resources to advance their promising antiviral research," said John C. Pottage, Jr., M.D., Lead Scientific Consultant for the INTREPID Alliance. "Providing these scientific tools and connection points to open-access collections in one stop, along with the opportunity to access INTREPID's advisory services could make the difference between developers advancing versus shelving their compounds at critical inflection points."
Alignment with Global Pandemic Preparedness
INTREPID's Antiviral Toolbox and landscape analysis serve as key contributions to the 100 Days Mission of the International Pandemic Preparedness Secretariat (搜索). This initiative aims to ensure that within the first 100 days of identifying a new pandemic threat, interventions can be made available that are safe, effective, and affordable.
The platform's information is regularly updated and freely available to support policymakers, funders, and the global scientific community in identifying the most urgent needs and highest-impact opportunities in antiviral R&D. Small-molecule antivirals (搜索) are recognized as indispensable tools for rapid, scalable, and equitable responses to epidemic and pandemic threats.
About INTREPID Alliance
The INTREPID Alliance (搜索) operates as a not-for-profit consortium of innovative biopharmaceutical companies and associations committed to accelerating antiviral research. The organization aims to ensure stronger pipeline development and better preparedness to respond to future pandemic and endemic threats through facilitating early science and R&D, policy and advocacy, and stakeholder engagement.
Launched in March 2023 at a high-level summit that brought together more than 100 thought leaders in virology and global health, INTREPID works with public, private, and not-for-profit sectors to bridge key gaps and unmet needs in delivering antiviral solutions to viral pathogens with the greatest pandemic potential.